Blueprint for antibody biologics developability

MAbs. 2023 Jan-Dec;15(1):2185924. doi: 10.1080/19420862.2023.2185924.


Large-molecule antibody biologics have revolutionized medicine owing to their superior target specificity, pharmacokinetic and pharmacodynamic properties, safety and toxicity profiles, and amenability to versatile engineering. In this review, we focus on preclinical antibody developability, including its definition, scope, and key activities from hit to lead optimization and selection. This includes generation, computational and in silico approaches, molecular engineering, production, analytical and biophysical characterization, stability and forced degradation studies, and process and formulation assessments. More recently, it is apparent these activities not only affect lead selection and manufacturability, but ultimately correlate with clinical progression and success. Emerging developability workflows and strategies are explored as part of a blueprint for developability success that includes an overview of the four major molecular properties that affect all developability outcomes: 1) conformational, 2) chemical, 3) colloidal, and 4) other interactions. We also examine risk assessment and mitigation strategies that increase the likelihood of success for moving the right candidate into the clinic.

Keywords: Antibody; biologics; colloidal; conformational; developability; formulation; manufacturability; specificity; stability.

Publication types

  • Review

MeSH terms

  • Antibodies
  • Biological Products* / therapeutic use
  • Risk Assessment
  • Workflow


  • Biological Products
  • Antibodies

Grants and funding

The author(s) reported there is no funding associated with the work featured in this article.